相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy and safety of sodium-glucose cotransporter 2 inhibitors initiation in patients with acute heart failure, with and without type 2 diabetes: a systematic review and meta-analysis
Husam M. Salah et al.
CARDIOVASCULAR DIABETOLOGY (2022)
Empagliflozin for Heart Failure With Preserved Left Ventricular Ejection Fraction With and Without Diabetes
Gerasimos Filippatos et al.
CIRCULATION (2022)
Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction Results of DAPA-HF
Pardeep S. Jhund et al.
CIRCULATION (2021)
Cardiorenal outcomes with dapagliflozin by baseline glucose-lowering agents: Post hoc analyses fromDECLARE-TIMI58
Avivit Cahn et al.
DIABETES OBESITY & METABOLISM (2021)
Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status Results From the EMPEROR-Reduced Trial
Stefan D. Anker et al.
CIRCULATION (2021)
Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials
Suetonia C. Palmer et al.
BMJ-BRITISH MEDICAL JOURNAL (2021)
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
Matthew J. Page et al.
BMJ-BRITISH MEDICAL JOURNAL (2021)
Effect of Empagliflozin on Erythropoietin Levels, Iron Stores, and Red Blood Cell Morphology in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease
C. David Mazer et al.
CIRCULATION (2020)
SGLT2 Inhibitors Produce Cardiorenal Benefits by Promoting Adaptive Cellular Reprogramming to Induce a State of Fasting Mimicry: A Paradigm Shift in Understanding Their Mechanism of Action
Milton Packer
DIABETES CARE (2020)
Association of glucose-lowering medications with cardiovascular outcomes: an umbrella review and evidence map
Jianhong Zhu et al.
LANCET DIABETES & ENDOCRINOLOGY (2020)
Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes
Mark C. Petrie et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Sodium-Glucose Cotransporter-2 inhibitors are potential therapeutic agents for treatment of non-diabetic heart failure patients
Yasuaki Nakagawa et al.
JOURNAL OF CARDIOLOGY (2020)
Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial
David Z I Cherney et al.
Lancet Diabetes & Endocrinology (2020)
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
Milton Packer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Dapagliflozin in Patients with Chronic Kidney Disease
Hiddo J. L. Heerspink et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial
David C Wheeler et al.
Lancet Diabetes & Endocrinology (2020)
Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease
Hiddo J. L. Heerspink et al.
DIABETOLOGIA (2019)
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
J. J. V. McMurray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
S. D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial
M. V. Karg et al.
CARDIOVASCULAR DIABETOLOGY (2018)
Improvement in Cardiovascular Outcomes With Empagliflozin Is Independent of Glycemic Control
Silvio E. Inzucchi et al.
CIRCULATION (2018)
How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial
Silvio E. Inzucchi et al.
DIABETES CARE (2018)
SGLT2 inhibitors and the kidney: Effects and mechanisms
V. Tsimihodimos et al.
DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS (2018)
Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation
Laween Uthman et al.
DIABETOLOGIA (2018)
The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study
William G. Herrington et al.
CLINICAL KIDNEY JOURNAL (2018)
Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects
Hiddo J. L. Heerspink et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2017)
Association of Intensive Blood Pressure Control and Kidney Disease Progression in Nondiabetic Patients With Chronic Kidney Disease A Systematic Review and Meta-analysis
Wan-Chuan Tsai et al.
JAMA INTERNAL MEDICINE (2017)
Do effects of sodium-glucose cotransporter-2 inhibitors in patients with diabetes give insight into potential use in non-diabetic kidney disease?
Harindra Rajasekeran et al.
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION (2017)
Differential Effects of Dapagliflozin on Cardiovascular Risk Factors at Varying Degrees of Renal Function
Sergei Petrykiv et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2017)
Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes
Ele Ferrannini et al.
DIABETES (2016)
Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis
Sunder Mudaliar et al.
DIABETES CARE (2016)
EMPA-REG - the diuretic hypothesis
John McMurray
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2016)
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors from Natural Products: Discovery of Next-Generation Antihyperglycemic Agents
Chang-Ik Choi
MOLECULES (2016)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus
David Z. I. Cherney et al.
CIRCULATION (2014)
分享论文
